| Literature DB >> 34549952 |
Vito A Taddeo1,2, Marvin J Núñez3, Manuela Beltrán4, Ulises G Castillo3, Jenny Menjívar5, Ignacio A Jiménez1, José Alcamí4, Luis M Bedoya4,6, Isabel L Bazzocchi1.
Abstract
The aim of the present study is to report the isolation, structural elucidation, and antiviral evaluation of four new withanolide-type steroids, named nicansteroidins A-D (1-4), together with nine related known compounds (5-13) isolated from the aerial parts of Physalis nicandroides. Their structures were established based on an extensive spectroscopic analysis, including 1D and 2D NMR techniques. Outstandingly, nicansteroidins A and B possess an unusual side chain with an exocyclic double bond on the δ-lactone system, whereas nicansteroidins C and D have an uncommon cycloperoxide functionality in ring A as distinct structural motifs. Their biological evaluation as inhibitors of human immunodeficiency virus type 1 replication revealed that two compounds from this series, 7 and 13, displayed strong inhibition of HIV-1 replication with IC50 values lower than 2 μM. Moreover, cellular mechanism experiments showed that the main target of these compounds in the HIV replication cycle is viral transcription. This study is the first report of withanolide-type steroids as HIV inhibitors and provides insight into their potential as candidates for further preclinical studies.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34549952 PMCID: PMC8946265 DOI: 10.1021/acs.jnatprod.1c00637
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050
Scheme 1Structures of Withasteroids 1–13 Isolated from Physalis nicandroides
1H NMR Spectroscopic Data for Compounds 1–5a
| position | |||||
|---|---|---|---|---|---|
| 2 | 6.02, dd (2.9, 10.0) | 6.02, dd (2.7, 10.1) | 4.45, dd (1.1, 6.3) | 7.00, dd (1.3, 8.4) | 6.02, dd (2.6, 10.1) |
| 3 | 6.87, ddd (2.3, 6.2, 10.0) | 6.86, ddd (2.3, 6.1, 10.1) | 6.62, dd (6.3, 8.4) | 6.66, dd (6.5, 8.4) | 6.86, ddd (2.6, 6.2, 10.1) |
| 4 | α 1.95, dd (6.2, 19.1) β 2.99, td (2.3, 19.1) | 1.95, dd (6.1, 19.1) 3.00, td (2.3, 19.1) | 7.02, dd (1.1,8.4) | 4.48, dd (1.3, 6.5) | 1.94, dd (6.2, 19.0) 2.98, td (2.6, 19.0) |
| 6 | 3.25, d (2.2) | 3.25, d (2.8) | 4.03, s | 4.08, s | 3.24, d (2.8) |
| 7 | 1.56, | 1.56, | 1.80, | 1.58, | 1.54, |
| 8 | 1.88, dt (3.3, 12.2) | 1.87, dt (3.2, 12.0) | 2.06 | 1.94 | 1.88, dt (3.3, 12.2) |
| 9 | 2.16 | 2.16, dt (4.4, 12.0) | 2.61, dt (3.5, 12.4) | 2.52, td (3.6, 12.4) | 2.16 |
| 11 | 1.46, | 1.54, | 1.39, | 1.38 | 1.45, |
| 12 | 1.58 | 1.55, | 1.50, | 1.59, | 1.53, |
| 15 | 5.06, dd (3.4, 8.6) | 5.06, dd (3.5, 8.5) | 5.30, d (2.5) | 5.07, s | 5.05, dd (3.5, 8.6) |
| 16 | 1.81, dd (3.4, 16.0) | 1.84, dd (3.5, 16.0) | 5.63, d (2.5) | 3.49, s | 1.80, dd (3.5, 16.0) |
| 2.66, dd (8.6, 16.0) | 2.65, dd (8.5, 16.0) | 2.65, dd (8.6, 16.0) | |||
| 18 | 1.17, s | 1.20, s | 1.16, s | 1.15, s | 1.12, s |
| 19 | 1.23, s | 1.25, s | 1.18, s | 1.20, s | 1.24, s |
| 20 | 2.27, dq (4.6, 7.0) | 2.25, dq (4.6, 7.1) | 2.50, q (7.0) | 2.60, dq (4.8, 7.2) | 2.24, dq (4.5, 7.0) |
| 21 | 1.05, d (7.0) | 1.00, d (7.1) | 1.10, d (7.0) | 1.01, d (7.2) | 1.06, d (7.0) |
| 22 | 4.65, td (2.5, 11.8) | 5.01, td (2.6, 12.1) | 4.30, ddd (3.6, 7.4,11.3) | 4.49, ddd (3.5, 4.8, 12.8) | 4.70, td (3.5, 12.8) |
| 23 | 2.34 | 2.62, dd (1.7, 15.4) | 2.29, d (16.6) | 2.12, d (3.5, 15.0) | 2.42, dd (2.4, 16.6) |
| 1.75, dd (11.8, 15.4) | 2.40, t (16.6) | 2.39, t (15.0) | 2.51, t (16.6) | ||
| 27 | 6.05, s; 6.64, s | 6.08, s; 6.72, s | 1.88, s | 1.88, t (1.1) | 1.87, s |
| 28 | 1.49, s | 1.55, s | 1.98, s | 1.94 | 1.92, s |
| OAc-15 | 1.99, s | 1.99, s | 2.11, s | 2.21 | 1.98, s |
| OH-14 | 2.92, s | 2.55, br s | 3.21, br s | 2.79, s | |
| OH-17 | 3.45, s | 3.57, s | 3.30, s | ||
| OH-24 | 2.93, s | 8.06, s |
Spectra recorded in CDCl3 at 600 MHz (J are given in parentheses in Hz). Data based on COSY, HSQC, and HMBC experiments.
Signals without multiplicity assignments were overlapping resonances deduced by HSQC experiments.
13C NMR Spectroscopic Data for Compounds 1–5a
| position | |||||
|---|---|---|---|---|---|
| 1 | 203.4, C | 203.1, C | 206.8, C | 206.2, C | 203.4, C |
| 2 | 128.8, CH | 128.8, CH | 78.6, CH | 78.8, CH | 129.2, CH |
| 3 | 144.9, CH | 144.8, CH | 126.3, CH | 126.0, CH | 145.1, CH |
| 4 | 32.9, CH2 | 32.9, CH2 | 142.2, CH | 141.9, CH | 33.3, CH2 |
| 5 | 61.9, C | 62.0, C | 84.1, C | 83.9, C | 83.9, C |
| 6 | 63.6, CH | 63.7, CH | 67.0, CH | 67.3, CH | 62.2, CH |
| 7 | 24.5, CH2 | 24.5, CH2 | 27.9, CH2 | 29.8, CH2 | 24.8, CH2 |
| 8 | 35.1, CH | 35.3, CH | 34.6, CH | 34.4, CH | 35.5, CH |
| 9 | 38.2, CH | 38.3, CH | 38.2, CH | 37.4, CH | 38.6, CH |
| 10 | 48.3, C | 48.3, C | 48.5, C | 48.1, C | 48.7, C |
| 11 | 22.6, CH2 | 22.6, CH2 | 21.9, CH2 | 20.7, CH2 | 22.8, CH2 |
| 12 | 30.4, CH2 | 30.2, CH2 | 38.5, CH2 | 32.4, CH2 | 30.3, CH2 |
| 13 | 50.4, C | 50.7, C | 52.3, C | 46.8, C | 50.8, C |
| 14 | 86.7, C | 86.8, C | 82.2, C | 81.6, C | 87.1, C |
| 15 | 79.5, CH | 79.5, CH | 83.1, CH | 76.8, CH | 79.9, CH |
| 16 | 48.3, CH2 | 47.9, CH2 | 120.6, CH | 59.3, CH | 48.6, CH2 |
| 17 | 86.0, C | 86.1, C | 161.5, C | 76.3, C | 86.4, C |
| 18 | 15.5, CH3 | 14.5, CH3 | 16.7, CH3 | 15.9, CH3 | 15.1, CH3 |
| 19 | 14.9, CH3 | 15.0, CH3 | 19.0, CH3 | 18.5, CH3 | 15.2, CH3 |
| 20 | 41.9, CH | 41.1, CH | 35.6, CH | 33.5, CH | 42.2, CH |
| 21 | 9.0, CH3 | 9.2, CH3 | 17.6, CH3 | 13.5, CH3 | 10.0, CH3 |
| 22 | 76.8, CH | 75.2, CH | 78.9, CH | 76.8, CH | 77.1, CH |
| 23 | 33.7, CH2 | 34.3, CH2 | 32.8, CH2 | 32.5, CH2 | 32.3, CH2 |
| 24 | 81.3, C | 80.2, C | 150.3, C | 149.3, C | 150.7, C |
| 25 | 139.0, C | 136.7, C | 121.8, C | 122.1, C | 121.8, C |
| 26 | 166.3, C | 165.7, C | 167.7, C | 166.4, C | 167.4, C |
| 27 | 129.3, CH2 | 132.3, CH2 | 12.5, CH3 | 12.6, CH2 | 12.7, CH3 |
| 28 | 25.1, CH3 | 23.4, CH3 | 20.8, CH3 | 20.6, CH3 | 20.9, CH3 |
| OAc-15 | 169.4, C | 169.4, C | 170.6, C | 170.2, C | 169.7, C |
| 21.4, CH3 | 21.4, CH3 | 21.3, CH3 | 22.8, CH3 | 21.7, CH3 |
Spectra recorded in CDCl3 at 150 MHz. Data based on DEPTs, HSQC, and HMBC experiments.
Overlapping signals.
Figure 1Selected HMBC (1H–13C) long-range correlations (→) and NOE effects (↔) for compounds 1 (left) and 3 (right).
Anti-HIV Activitya and Cytotoxicityb of Withasteroids 1–13
| compound | IC50 | CC50 | SI |
|---|---|---|---|
| 12.4 (9.5–16.4; 0.8945) | >100 | >8 | |
| 18.7 (13.6–25.9; 0.8333) | >100 | >5.3 | |
| 76.1 (44.9–143.6; 0.7311) | >100 | >1.3 | |
| 72.7 (49.8–111.3; 0.8528) | >100 | >1.4 | |
| >100 | >100 | ||
| 1.9 (0.8–2.7; 0.778) | 16.0 (8.4–31.4; 0.8139) | 10.6 | |
| 67.9 (46.7–103.2; 0.86) | >100 | >1.5 | |
| 8.9 (6.2–13.1; 0.8256) | >100 | >11.2 | |
| 32.7 (24.8–43.6; 0.834) | >100 | >3.1 | |
| 21.1 (14.9–30.1; 0.8075) | >100 | >4.7 | |
| 1.0 (0.6–1.7; 0.8056) | 15.2 (6.8–35.8; 0.7353) | 15.5 | |
| TFV | 1.7 (1.1–2.5; 0.9387) | >100 | 333 |
IC50 (inhibitory concentration 50%) values were calculated using GrapPad Pris software. All values are the mean of at least three independent experiments.
CC50 (cytotoxic concentration 50%) values were calculated using GrapPad Pris software. All values are the mean of at least three independent experiments.
R2: R squared.
SI: selectivity index (CC50/IC50).
TFV: tenofovir used as an antiretroviral drug control.
Entry Inhibition and Transcriptional Anti-HIV Activity of Withasteroids 7 and 13
| compound | IC50 HIV | IC50 VSV-HIV
(CI95%; | IC50 viral
transcription (CI95%; | SI | SI |
|---|---|---|---|---|---|
| 1.94 | 3.20 | 1.97 | 1.64 | 1.02 | |
| (1.25–2.99; 0.8345) | (1.74–5.88; 0.7624) | (1.38–2.79; 0.8023) | (0.7896) | (0.8079) | |
| 1.01 | 2.67 | 1.14 | 2.66 | 1.13 | |
| (0.67–1.48; 0.8684) | (1.55–4.56; 0.8136) | (082–1.58; 0,8174) | (0.7408) | (0.6666) | |
| enfuvirtide | 0.015 | >1 | 0.01 | >66.67 | |
| (0.009–0.023; 0.9798) | (0.009–0.023; 0.9798) | ||||
| TFV | 1.69 | ||||
| (1.06–2.75; 0.9387) |
IC50 (inhibitory concentration 50%) values were calculated using GraphPad Prism software.
CI95% (confidence interval 95%).
R2: R squared.
Specificity index: SI VSV-HIV/HIV is the relationship between the IC50 value obtained in VSV-HIV infection experiments and the IC50 from HIV infection experiments. SI HIV transcription/HIV infection is the relationship between the IC50 value obtained in transcription experiments and the IC50 value from HIV infection experiments. All values are the means of at least three independent experiments. IC50 values in HIV infection are repeated here from Table to better compare with values of entry and transcription inhibition.
Figure 2(A) In vitro evaluation of the anti-HIV activity and cytotoxicity of isolated compounds. MT-2 cells were infected with an X4 recombinant HIV (NL4.3-Ren, 100.000 RLUs or 20 ng p24/well) or with a VSV pseudotyped HIV (VSV-HIV, 100.000 RLUs or 20 ng p24/well) in the presence of different concentrations of test compounds or the fusion inhibitor enfuvirtide for 48 h. The same concentration of vehicle (DMSO or water) was used as a nontreated control (100%). The cell culture was then lysed, and relative luminescence units (RLUs) were measured in a luminometer. Cell viability was evaluated in mock-infected cells in parallel using the CellTiter Glo reagent (Promega). (B) Effect of isolated compounds on HIV transcription. MT-2 cells were transfected with a pNL4.3-Luc plasmid (1 ng/106 cells) and treated or nontreated with serial dilutions of the test compounds for 48 h. The same concentration of vehicle (DMSO) was used as a nontreated control (100%). The cell culture was then lysed, and RLUs were measured in a luminometer. Results were analyzed using GraphPad software.